ID   EPHA2_HUMAN             Reviewed;         976 AA.
AC   P29317; Q8N3Z2;
DT   01-DEC-1992, integrated into UniProtKB/Swiss-Prot.
DT   05-MAY-2009, sequence version 2.
DT   02-NOV-2010, entry version 133.
DE   RecName: Full=Ephrin type-A receptor 2;
DE            EC=2.7.10.1;
DE   AltName: Full=Epithelial cell kinase;
DE   AltName: Full=Tyrosine-protein kinase receptor ECK;
DE   Flags: Precursor;
GN   Name=EPHA2; Synonyms=ECK;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Epithelium;
RX   MEDLINE=91061738; PubMed=2174105;
RA   Lindberg R.A., Hunter T.;
RT   "cDNA cloning and characterization of eck, an epithelial cell receptor
RT   protein-tyrosine kinase in the eph/elk family of protein kinases.";
RL   Mol. Cell. Biol. 10:6316-6324(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-588; TYR-594; TYR-772;
RP   TYR-921 AND TYR-930, AND MASS SPECTROMETRY.
RC   TISSUE=Mammary epithelium;
RX   PubMed=15951569; DOI=10.1074/mcp.M500089-MCP200;
RA   Zhang Y., Wolf-Yadlin A., Ross P.L., Pappin D.J., Rush J.,
RA   Lauffenburger D.A., White F.M.;
RT   "Time-resolved mass spectrometry of tyrosine phosphorylation sites in
RT   the epidermal growth factor receptor signaling network reveals dynamic
RT   modules.";
RL   Mol. Cell. Proteomics 4:1240-1250(2005).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-575; TYR-588; TYR-594
RP   AND TYR-772, AND MASS SPECTROMETRY.
RC   TISSUE=Lung carcinoma;
RX   PubMed=18083107; DOI=10.1016/j.cell.2007.11.025;
RA   Rikova K., Guo A., Zeng Q., Possemato A., Yu J., Haack H., Nardone J.,
RA   Lee K., Reeves C., Li Y., Hu Y., Tan Z., Stokes M., Sullivan L.,
RA   Mitchell J., Wetzel R., Macneill J., Ren J.M., Yuan J.,
RA   Bakalarski C.E., Villen J., Kornhauser J.M., Smith B., Li D., Zhou X.,
RA   Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.;
RT   "Global survey of phosphotyrosine signaling identifies oncogenic
RT   kinases in lung cancer.";
RL   Cell 131:1190-1203(2007).
RN   [7]
RP   TISSUE SPECIFICITY.
RX   PubMed=17332925;
RA   Liu D.-P., Wang Y., Koeffler H.P., Xie D.;
RT   "Ephrin-A1 is a negative regulator in glioma through down-regulation
RT   of EphA2 and FAK.";
RL   Int. J. Oncol. 30:865-871(2007).
RN   [8]
RP   INTERACTION WITH INPPL1.
RX   PubMed=17135240; DOI=10.1074/jbc.M608509200;
RA   Zhuang G., Hunter S., Hwang Y., Chen J.;
RT   "Regulation of EphA2 receptor endocytosis by SHIP2 lipid phosphatase
RT   via phosphatidylinositol 3-Kinase-dependent Rac1 activation.";
RL   J. Biol. Chem. 282:2683-2694(2007).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-570; TYR-594; TYR-772;
RP   SER-897; THR-898 AND SER-901, AND MASS SPECTROMETRY.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=17192257; DOI=10.1074/mcp.T600062-MCP200;
RA   Wissing J., Jaensch L., Nimtz M., Dieterich G., Hornberger R.,
RA   Keri G., Wehland J., Daub H.;
RT   "Proteomics analysis of protein kinases by target class-selective
RT   prefractionation and tandem mass spectrometry.";
RL   Mol. Cell. Proteomics 6:537-547(2007).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-575; TYR-588 AND
RP   TYR-772, AND MASS SPECTROMETRY.
RC   TISSUE=Mammary epithelium;
RX   PubMed=17389395; DOI=10.1073/pnas.0608638104;
RA   Wolf-Yadlin A., Hautaniemi S., Lauffenburger D.A., White F.M.;
RT   "Multiple reaction monitoring for robust quantitative proteomic
RT   analysis of cellular signaling networks.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:5860-5865(2007).
RN   [11]
RP   FUNCTION, AND INDUCTION.
RX   PubMed=18339848; DOI=10.1158/0008-5472.CAN-07-2372;
RA   Zhang G., Njauw C.-N., Park J.M., Naruse C., Asano M., Tsao H.;
RT   "EphA2 is an essential mediator of UV radiation-induced apoptosis.";
RL   Cancer Res. 68:1691-1696(2008).
RN   [12]
RP   SUBCELLULAR LOCATION, AND PHOSPHORYLATION.
RX   PubMed=18794797; DOI=10.1038/onc.2008.328;
RA   Wykosky J., Palma E., Gibo D.M., Ringler S., Turner C.P., Debinski W.;
RT   "Soluble monomeric EphrinA1 is released from tumor cells and is a
RT   functional ligand for the EphA2 receptor.";
RL   Oncogene 27:7260-7273(2008).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-570; TYR-575; SER-579;
RP   TYR-594; TYR-628; THR-647; TYR-772; SER-897; THR-898; SER-899 AND
RP   SER-901, AND MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-570; SER-892 AND
RP   SER-901, AND MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [15]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-435, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-575; TYR-588; TYR-594;
RP   TYR-772 AND TYR-960, AND MASS SPECTROMETRY.
RC   TISSUE=Mammary epithelium;
RX   PubMed=19534553; DOI=10.1021/pr900044c;
RA   Heibeck T.H., Ding S.-J., Opresko L.K., Zhao R., Schepmoes A.A.,
RA   Yang F., Tolmachev A.V., Monroe M.E., Camp D.G. II, Smith R.D.,
RA   Wiley H.S., Qian W.-J.;
RT   "An extensive survey of tyrosine phosphorylation revealing new sites
RT   in human mammary epithelial cells.";
RL   J. Proteome Res. 8:3852-3861(2009).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-153; SER-373; SER-570;
RP   TYR-575; THR-587; TYR-588; THR-593; TYR-594; TYR-628; THR-647;
RP   THR-771; TYR-772; SER-790; TYR-791; SER-869; SER-880; SER-897;
RP   THR-898; SER-899; SER-901; SER-910 AND TYR-960, AND MASS SPECTROMETRY.
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 596-900.
RX   MEDLINE=22357219; PubMed=12467573; DOI=10.1016/S0969-2126(02)00907-3;
RA   Nowakowski J., Cronin C.N., McRee D.E., Knuth M.W., Nelson C.G.,
RA   Pavletich N.P., Rogers J., Sang B.C., Scheibe D.N., Swanson R.V.,
RA   Thompson D.A.;
RT   "Structures of the cancer-related Aurora-A, FAK, and EphA2 protein
RT   kinases from nanovolume crystallography.";
RL   Structure 10:1659-1667(2002).
RN   [19]
RP   STRUCTURE BY NMR OF 902-976.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the C-terminal SAM-domain of EPHAA2: ephrin
RT   type-A receptor 2 precursor (EC 2.7.10.1).";
RL   Submitted (JAN-2008) to the PDB data bank.
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (2.52 ANGSTROMS) OF 28-201, X-RAY
RP   CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 28-201 IN COMPLEX WITH EFNA1,
RP   SUBUNIT, DISULFIDE BOND, AND MUTAGENESIS OF ARG-103.
RX   PubMed=19525919; DOI=10.1038/embor.2009.91;
RA   Himanen J.P., Goldgur Y., Miao H., Myshkin E., Guo H., Buck M.,
RA   Nguyen M., Rajashankar K.R., Wang B., Nikolov D.B.;
RT   "Ligand recognition by A-class Eph receptors: crystal structures of
RT   the EphA2 ligand-binding domain and the EphA2/ephrin-A1 complex.";
RL   EMBO Rep. 10:722-728(2009).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 25-202, AND DISULFIDE BOND.
RG   Structural genomics consortium (SGC);
RT   "Ephrin A1 bound to the ligand binding domain of the human ephrin A2
RT   (EPHA2) receptor protein kinase.";
RL   Submitted (FEB-2009) to the PDB data bank.
RN   [22]
RP   STRUCTURE BY NMR OF 523-563.
RA   Mayzel M.L., Bocharov E.V., Volynsky P.E., Arseniev A.S.;
RT   "Left-handed dimer of EPHA2 transmembrane domain helix packing
RT   diversity among receptor tyrosine kinases.";
RL   Submitted (AUG-2009) to the PDB data bank.
RN   [23]
RP   VARIANTS [LARGE SCALE ANALYSIS] ARG-391; MET-511; HIS-568; SER-777 AND
RP   HIS-876.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [24]
RP   VARIANT CTPP1 TRP-948, AND INVOLVEMENT IN AGE-RELATED CATARACTS.
RX   PubMed=19005574;
RA   Shiels A., Bennett T.M., Knopf H.L.S., Maraini G., Li A., Jiao X.,
RA   Hejtmancik J.F.;
RT   "The EPHA2 gene is associated with cataracts linked to chromosome
RT   1p.";
RL   Mol. Vis. 14:2042-2055(2008).
RN   [25]
RP   VARIANT CTPP1 ILE-940.
RX   PubMed=19306328; DOI=10.1002/humu.20995;
RA   Zhang T., Hua R., Xiao W., Burdon K.P., Bhattacharya S.S., Craig J.E.,
RA   Shang D., Zhao X., Mackey D.A., Moore A.T., Luo Y., Zhang J.,
RA   Zhang X.;
RT   "Mutations of the EPHA2 receptor tyrosine kinase gene cause autosomal
RT   dominant congenital cataract.";
RL   Hum. Mutat. 30:E603-E611(2009).
RN   [26]
RP   VARIANT ARCC2 GLN-721, AND CHARACTERIZATION OF VARIANT ARCC2 GLN-721.
RX   PubMed=19649315; DOI=10.1371/journal.pgen.1000584;
RA   Jun G., Guo H., Klein B.E., Klein R., Wang J.J., Mitchell P., Miao H.,
RA   Lee K.E., Joshi T., Buck M., Chugha P., Bardenstein D., Klein A.P.,
RA   Bailey-Wilson J.E., Gong X., Spector T.D., Andrew T., Hammond C.J.,
RA   Elston R.C., Iyengar S.K., Wang B.;
RT   "EPHA2 is associated with age-related cortical cataract in mice and
RT   humans.";
RL   PLoS Genet. 5:E1000584-E1000584(2009).
CC   -!- FUNCTION: Receptor for members of the ephrin-A family. Binds to
CC       ephrin-A1, -A3, -A4 and -A5. Plays an important role in
CC       angiogenesis and tumor neovascularization. The recruitement of
CC       VAV2, VAV3 and PI3-kinase p85 subunit by phosphorylated EPHA2 is
CC       critical for EFNA1-induced RAC1 GTPase activation and vascular
CC       endothelial cell migration and assembly (By similarity). Induces
CC       apoptosis in a TP53/p53-independent, caspase-8-dependent manner.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate.
CC   -!- SUBUNIT: Monomer at low protein concentrations (around 10 uM) and
CC       forms homodimers at higher concentrations. Forms heterodimers with
CC       EFNA1. Interacts with SLA. The phosphorylated form interacts with
CC       VAV2, VAV3 and PI3-kinase p85 subunit (By similarity). Interacts
CC       with INPPL1/SHIP2.
CC   -!- INTERACTION:
CC       P20827:EFNA1; NbExp=3; IntAct=EBI-702104, EBI-715194;
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane
CC       protein.
CC   -!- TISSUE SPECIFICITY: Expressed in brain and glioma tissue and
CC       glioma cell lines (at protein level). Expressed most highly in
CC       tissues that contain a high proportion of epithelial cells, e.g.,
CC       skin, intestine, lung, and ovary.
CC   -!- INDUCTION: By UV irradiation via a TP53/p53-independent, but MAPK-
CC       dependent, mechanism.
CC   -!- PTM: Activated by EFNA1 via tyrosine phosphorylation.
CC       Phosphorylated residues Tyr-588 and Tyr-594 are required for
CC       binding VAV2 and VAV3 while phosphorylated residues Tyr-735 and
CC       Tyr-930 are required for binding PI3-kinase p85 subunit. These
CC       phosphorylated residues are critical for recruitment of VAV2 and
CC       VAV3 and PI3-kinase p85 subunit which transduce downstream
CC       signaling to activate RAC1 GTPase and endothelial cell migration.
CC       They also play a critical role in transducing EPHA2 signaling in
CC       vascular endothelial cells during tumor angiogenesis (By
CC       similarity).
CC   -!- DISEASE: Genetic variations in EPHA2 are the cause of
CC       susceptibility to cataract cortical age-related type 2 (ARCC2)
CC       [MIM:613020]. A developmental punctate opacity common in the
CC       cortex and present in most lenses. The cataract is white or
CC       cerulean, increases in number with age, but rarely affects vision.
CC   -!- DISEASE: Defects in EPHA2 are the cause of cataract posterior
CC       polar type 1 (CTPP1) [MIM:116600]. A subcapsular opacity, usually
CC       disk-shaped, located at the back of the lens. It can have a marked
CC       effect on visual acuity.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Ephrin receptor subfamily.
CC   -!- SIMILARITY: Contains 2 fibronectin type-III domains.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -!- SIMILARITY: Contains 1 SAM (sterile alpha motif) domain.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M59371; AAA53375.1; -; mRNA.
DR   EMBL; AL451042; CAH71943.1; -; Genomic_DNA.
DR   EMBL; CH471167; EAW51769.1; -; Genomic_DNA.
DR   EMBL; BC037166; AAH37166.1; -; mRNA.
DR   IPI; IPI00021267; -.
DR   PIR; A36355; A36355.
DR   RefSeq; NP_004422.2; -.
DR   UniGene; Hs.171596; -.
DR   PDB; 1MQB; X-ray; 2.30 A; A/B=596-900.
DR   PDB; 2E8N; NMR; -; A=902-976.
DR   PDB; 2K9Y; NMR; -; A/B=523-563.
DR   PDB; 2X10; X-ray; 3.00 A; A=27-534.
DR   PDB; 2X11; X-ray; 4.83 A; A=27-534.
DR   PDB; 3C8X; X-ray; 1.95 A; A=23-202.
DR   PDB; 3CZU; X-ray; 2.65 A; A=23-202.
DR   PDB; 3FL7; X-ray; 2.50 A; A=23-531.
DR   PDB; 3HEI; X-ray; 2.00 A; A/C/E/G/I/K/M/O=28-201.
DR   PDB; 3HPN; X-ray; 2.52 A; A/B/C/D/E/F=28-201.
DR   PDB; 3KKA; X-ray; 2.40 A; C/D/E=903-971.
DR   PDB; 3MBW; X-ray; 2.81 A; A=23-326.
DR   PDB; 3MX0; X-ray; 3.51 A; A/C=27-435.
DR   PDBsum; 1MQB; -.
DR   PDBsum; 2E8N; -.
DR   PDBsum; 2K9Y; -.
DR   PDBsum; 2X10; -.
DR   PDBsum; 2X11; -.
DR   PDBsum; 3C8X; -.
DR   PDBsum; 3CZU; -.
DR   PDBsum; 3FL7; -.
DR   PDBsum; 3HEI; -.
DR   PDBsum; 3HPN; -.
DR   PDBsum; 3KKA; -.
DR   PDBsum; 3MBW; -.
DR   PDBsum; 3MX0; -.
DR   ProteinModelPortal; P29317; -.
DR   DIP; DIP-96N; -.
DR   IntAct; P29317; 9.
DR   MINT; MINT-3972729; -.
DR   STRING; P29317; -.
DR   PhosphoSite; P29317; -.
DR   PRIDE; P29317; -.
DR   Ensembl; ENST00000358432; ENSP00000351209; ENSG00000142627.
DR   Ensembl; ENST00000407976; ENSP00000384858; ENSG00000142627.
DR   GeneID; 1969; -.
DR   KEGG; hsa:1969; -.
DR   CTD; 1969; -.
DR   GeneCards; GC01M016450; -.
DR   H-InvDB; HIX0023618; -.
DR   HGNC; HGNC:3386; EPHA2.
DR   HPA; CAB010464; -.
DR   MIM; 116600; phenotype.
DR   MIM; 176946; gene.
DR   MIM; 613020; phenotype.
DR   Orphanet; 98993; Posterior polar cataract.
DR   Orphanet; 98994; Total congenital cataract.
DR   PharmGKB; PA27818; -.
DR   eggNOG; prNOG08660; -.
DR   HOGENOM; HBG755340; -.
DR   HOVERGEN; HBG062180; -.
DR   InParanoid; P29317; -.
DR   OMA; VHEFQTL; -.
DR   OrthoDB; EOG9JDKSD; -.
DR   PhylomeDB; P29317; -.
DR   BRENDA; 2.7.10.1; 247.
DR   Pathway_Interaction_DB; epha_fwdpathway; EPHA forward signaling.
DR   Pathway_Interaction_DB; epha2_fwdpathway; EPHA2 forward signaling.
DR   Pathway_Interaction_DB; ephrina_ephapathway; EphrinA-EPHA pathway.
DR   DrugBank; DB01254; Dasatinib.
DR   NextBio; 7983; -.
DR   ArrayExpress; P29317; -.
DR   Bgee; P29317; -.
DR   CleanEx; HS_EPHA2; -.
DR   Genevestigator; P29317; -.
DR   GermOnline; ENSG00000142627; Homo sapiens.
DR   GO; GO:0005887; C:integral to plasma membrane; TAS:ProtInc.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005003; F:ephrin receptor activity; IEA:InterPro.
DR   GO; GO:0005515; F:protein binding; IPI:IntAct.
DR   GO; GO:0001525; P:angiogenesis; IEA:UniProtKB-KW.
DR   GO; GO:0006915; P:apoptosis; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein amino acid phosphorylation; IEA:InterPro.
DR   GO; GO:0043535; P:regulation of blood vessel endothelial cell...; ISS:UniProtKB.
DR   InterPro; IPR001090; Ephrin_rcpt_lig-bd.
DR   InterPro; IPR008957; Fibronectin_III_dom.
DR   InterPro; IPR003961; FN_III.
DR   InterPro; IPR008979; Galactose-bd-like.
DR   InterPro; IPR009030; Growth_fac_rcpt.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001660; SAM.
DR   InterPro; IPR013761; SAM_type.
DR   InterPro; IPR021129; SAM_type1.
DR   InterPro; IPR001245; Ser-Thr/Tyr-Pkinase.
DR   InterPro; IPR010993; Sterile_alpha_motif_homology.
DR   InterPro; IPR020635; Tyr_Pkinase_cat_dom.
DR   InterPro; IPR020685; Tyr_prot_kinase.
DR   InterPro; IPR008266; Tyr_prot_kinase_AS.
DR   InterPro; IPR020770; Tyr_prot_kinase_Eph-A1/A2_rcpt.
DR   InterPro; IPR016257; Tyr_prot_kinase_ephrin_rcpt.
DR   InterPro; IPR001426; Tyr_prot_kinase_rcpt_V_CS.
DR   Gene3D; G3DSA:2.60.40.10; Ig-like_fold; 2.
DR   Gene3D; G3DSA:1.10.150.50; SAM_type; 1.
DR   PANTHER; PTHR23256; Tyr_prot_kinase; 1.
DR   PANTHER; PTHR23256:SF280; Tyr_prot_kinase_Eph-A1/A2_rcpt; 1.
DR   Pfam; PF01404; Ephrin_lbd; 1.
DR   Pfam; PF00041; fn3; 2.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF00536; SAM_1; 1.
DR   PIRSF; PIRSF000666; TyrPK_ephrin_receptor; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00615; EPH_lbd; 1.
DR   SMART; SM00060; FN3; 2.
DR   SMART; SM00454; SAM; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF49265; FN_III-like; 2.
DR   SUPFAM; SSF49785; Gal_bind_like; 1.
DR   SUPFAM; SSF57184; Grow_fac_recept; 1.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   SUPFAM; SSF47769; SAM_homology; 1.
DR   PROSITE; PS50853; FN3; 2.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00790; RECEPTOR_TYR_KIN_V_1; 1.
DR   PROSITE; PS00791; RECEPTOR_TYR_KIN_V_2; 1.
DR   PROSITE; PS50105; SAM_DOMAIN; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Angiogenesis; Apoptosis; ATP-binding; Cataract;
KW   Complete proteome; Disease mutation; Disulfide bond; Glycoprotein;
KW   Kinase; Membrane; Nucleotide-binding; Phosphoprotein; Polymorphism;
KW   Receptor; Repeat; Signal; Transferase; Transmembrane;
KW   Transmembrane helix; Tyrosine-protein kinase.
FT   SIGNAL        1     24       Potential.
FT   CHAIN        25    976       Ephrin type-A receptor 2.
FT                                /FTId=PRO_0000016800.
FT   TOPO_DOM     25    534       Extracellular (Potential).
FT   TRANSMEM    535    558       Helical; (Potential).
FT   TOPO_DOM    559    976       Cytoplasmic (Potential).
FT   DOMAIN      328    429       Fibronectin type-III 1.
FT   DOMAIN      435    526       Fibronectin type-III 2.
FT   DOMAIN      613    875       Protein kinase.
FT   DOMAIN      904    968       SAM.
FT   NP_BIND     619    627       ATP (By similarity).
FT   MOTIF       974    976       PDZ-binding (Potential).
FT   COMPBIAS    188    325       Cys-rich.
FT   ACT_SITE    739    739       Proton acceptor (By similarity).
FT   BINDING     646    646       ATP (By similarity).
FT   MOD_RES     153    153       Phosphoserine.
FT   MOD_RES     373    373       Phosphoserine.
FT   MOD_RES     570    570       Phosphoserine.
FT   MOD_RES     575    575       Phosphotyrosine.
FT   MOD_RES     579    579       Phosphoserine.
FT   MOD_RES     587    587       Phosphothreonine.
FT   MOD_RES     588    588       Phosphotyrosine; by autocatalysis (By
FT                                similarity).
FT   MOD_RES     593    593       Phosphothreonine.
FT   MOD_RES     594    594       Phosphotyrosine; by autocatalysis.
FT   MOD_RES     628    628       Phosphotyrosine.
FT   MOD_RES     647    647       Phosphothreonine.
FT   MOD_RES     735    735       Phosphotyrosine; by autocatalysis (By
FT                                similarity).
FT   MOD_RES     771    771       Phosphothreonine.
FT   MOD_RES     772    772       Phosphotyrosine; by autocatalysis.
FT   MOD_RES     790    790       Phosphoserine.
FT   MOD_RES     791    791       Phosphotyrosine.
FT   MOD_RES     869    869       Phosphoserine.
FT   MOD_RES     880    880       Phosphoserine.
FT   MOD_RES     892    892       Phosphoserine.
FT   MOD_RES     897    897       Phosphoserine.
FT   MOD_RES     898    898       Phosphothreonine.
FT   MOD_RES     899    899       Phosphoserine.
FT   MOD_RES     901    901       Phosphoserine.
FT   MOD_RES     910    910       Phosphoserine.
FT   MOD_RES     921    921       Phosphotyrosine; by autocatalysis
FT                                (Potential).
FT   MOD_RES     930    930       Phosphotyrosine.
FT   MOD_RES     960    960       Phosphotyrosine.
FT   CARBOHYD    407    407       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    435    435       N-linked (GlcNAc...).
FT   DISULFID     70    188
FT   DISULFID    105    115
FT   VARIANT      99     99       K -> N (in dbSNP:rs1058372).
FT                                /FTId=VAR_055989.
FT   VARIANT     391    391       G -> R (in dbSNP:rs34192549).
FT                                /FTId=VAR_042121.
FT   VARIANT     511    511       T -> M (in dbSNP:rs55747232).
FT                                /FTId=VAR_042122.
FT   VARIANT     568    568       R -> H (in dbSNP:rs56198600).
FT                                /FTId=VAR_042123.
FT   VARIANT     631    631       M -> T (in dbSNP:rs34021505).
FT                                /FTId=VAR_055990.
FT   VARIANT     721    721       R -> Q (in ARCC2; alters EPHA2
FT                                signaling).
FT                                /FTId=VAR_062532.
FT   VARIANT     777    777       G -> S (in a gastric adenocarcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_042124.
FT   VARIANT     876    876       R -> H (in dbSNP:rs35903225).
FT                                /FTId=VAR_042125.
FT   VARIANT     940    940       T -> I (in CTPP1).
FT                                /FTId=VAR_058907.
FT   VARIANT     948    948       G -> W (in CTPP1).
FT                                /FTId=VAR_058908.
FT   MUTAGEN     103    103       R->E: Significantly reduced response to
FT                                EFNA1.
FT   CONFLICT     94     99       IFIELK -> NNFELN (in Ref. 1; AAA53375).
FT   TURN        610    612
FT   STRAND      613    621
FT   STRAND      623    633
FT   STRAND      640    648
FT   HELIX       654    668
FT   STRAND      678    682
FT   STRAND      684    693
FT   HELIX       700    706
FT   TURN        707    709
FT   HELIX       713    732
FT   HELIX       742    744
FT   STRAND      745    747
FT   STRAND      753    755
FT   HELIX       781    783
FT   HELIX       786    790
FT   HELIX       796    811
FT   TURN        817    820
FT   HELIX       823    831
FT   HELIX       844    853
FT   TURN        858    860
FT   HELIX       864    876
FT   HELIX       878    882
FT   HELIX       909    915
FT   HELIX       919    921
FT   HELIX       922    928
FT   HELIX       933    936
FT   HELIX       943    946
FT   HELIX       952    970
SQ   SEQUENCE   976 AA;  108266 MW;  845D7E1BBCCAACCC CRC64;
     MELQAARACF ALLWGCALAA AAAAQGKEVV LLDFAAAGGE LGWLTHPYGK GWDLMQNIMN
     DMPIYMYSVC NVMSGDQDNW LRTNWVYRGE AERIFIELKF TVRDCNSFPG GASSCKETFN
     LYYAESDLDY GTNFQKRLFT KIDTIAPDEI TVSSDFEARH VKLNVEERSV GPLTRKGFYL
     AFQDIGACVA LLSVRVYYKK CPELLQGLAH FPETIAGSDA PSLATVAGTC VDHAVVPPGG
     EEPRMHCAVD GEWLVPIGQC LCQAGYEKVE DACQACSPGF FKFEASESPC LECPEHTLPS
     PEGATSCECE EGFFRAPQDP ASMPCTRPPS APHYLTAVGM GAKVELRWTP PQDSGGREDI
     VYSVTCEQCW PESGECGPCE ASVRYSEPPH GLTRTSVTVS DLEPHMNYTF TVEARNGVSG
     LVTSRSFRTA SVSINQTEPP KVRLEGRSTT SLSVSWSIPP PQQSRVWKYE VTYRKKGDSN
     SYNVRRTEGF SVTLDDLAPD TTYLVQVQAL TQEGQGAGSK VHEFQTLSPE GSGNLAVIGG
     VAVGVVLLLV LAGVGFFIHR RRKNQRARQS PEDVYFSKSE QLKPLKTYVD PHTYEDPNQA
     VLKFTTEIHP SCVTRQKVIG AGEFGEVYKG MLKTSSGKKE VPVAIKTLKA GYTEKQRVDF
     LGEAGIMGQF SHHNIIRLEG VISKYKPMMI ITEYMENGAL DKFLREKDGE FSVLQLVGML
     RGIAAGMKYL ANMNYVHRDL AARNILVNSN LVCKVSDFGL SRVLEDDPEA TYTTSGGKIP
     IRWTAPEAIS YRKFTSASDV WSFGIVMWEV MTYGERPYWE LSNHEVMKAI NDGFRLPTPM
     DCPSAIYQLM MQCWQQERAR RPKFADIVSI LDKLIRAPDS LKTLADFDPR VSIRLPSTSG
     SEGVPFRTVS EWLESIKMQQ YTEHFMAAGY TAIEKVVQMT NDDIKRIGVR LPGHQKRIAY
     SLLGLKDQVN TVGIPI
//
